Investment analysts at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a report released on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Up 4.2 %
Shares of AKTX opened at $2.36 on Friday. The business’s 50 day moving average is $3.12 and its two-hundred day moving average is $2.74. Akari Therapeutics has a 52-week low of $1.08 and a 52-week high of $4.40.
About Akari Therapeutics
Recommended Stories
- Five stocks we like better than Akari Therapeutics
- How to Start Investing in Real Estate
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Insider Trading – What You Need to Know
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Best Aerospace Stocks Investing
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.